In addition, EA treatment inhibits microglia-mediated neuroinflammation through inactivation of p38 MAPK and MyD88, accompanied by the decrease of IL-1β, IL-6, and TNF-α after ischemic stroke (Liu et al., 2016). This evidence concerns the gene IL1B and ischemic stroke.